Diferencia entre revisiones de «Aripiprazole»
Sin resumen de edición |
|||
| Línea 49: | Línea 49: | ||
==See Also== | ==See Also== | ||
*[[Antipsychotics]] | *[[Antipsychotics]] | ||
*[[Antipsychotic toxicity]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] [[Category:Psychiatry]] | [[Category:Pharmacology]] [[Category:Psychiatry]] | ||
Revisión actual - 04:08 7 mar 2021
Administration
- Type: Atypical antipsychotic
- Dosage Forms: tablet, oral disintegrating tablet, oral solution, extended-release injectable IM suspension
- Routes of Administration: PO, IM depot
- Common Trade Names: Abilify, Maintena, Aristada
Adult Dosing
- 2-30 mg PO daily
Pediatric Dosing
- > 6yo: 2-30 mg PO daily (slower titration up)
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Concomitant use of CYP3A4 or CYP2D6 inhibitors: reduce dose
- Concomitant use of CYP3A4 inducers: increase dose
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Cardiac arrest, cardiac failure, prolonged QT, MI
- Neuroleptic malignant syndrome, hyperthermia, rhabdomyolysis
- Seizure, stroke
- Tardive dyskinesia
- Agranulocytosis, leukopenia
- Angioedema
- Pancreatitis
- DKA
- Suicidal behavior
Common
- Somnolence, dizziness, akathisia, anxiety, insomnia, headache
- Extrapyramidal symptoms, tremor
- Nausea, vomiting, constipation
- Weight gain
Pharmacology
- Half-life: ~75 hours
- Metabolism: Hepatic via CYP2D6 and CYP3A4
- Excretion: Mostly fecal
Mechanism of Action
- Not well understood. D2 and HT2A antagonist, D3 and 5HT1A partial agonist